Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and protein kinase A

Thrombosis and Haemostasis

Volumn 90, Issue 4, 2003, Pages 577-585

  Dormond, Olivier ^a   Rüegg, Curzio ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

Adhesion receptors; Cell matrix interactions; Endothelial cells; Integrins; Prostaglandins

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; CELECOXIB; CELL ADHESION RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GUANOSINE TRIPHOSPHATASE; INTEGRIN; INTEGRIN ANTAGONIST; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN CDC42; RAC PROTEIN; RECEPTOR; ROFECOXIB; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; VU 08;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON POLYP; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REGULATION; GENE MUTATION; GLANZMANN DISEASE; HUMAN; METASTASIS; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 0142124293     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-03-0196     Document Type: Review

References (134)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000; 50: 63-70.
3. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
5. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
7. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-62.
8. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
9. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
10. Hynes RO. Cell adhesion: Old and new questions. Trends Cell Biol 1999; 9: M33-7.
11. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. Journal of Biological Chemistry. 2000; 275: 21785-8.
12. Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 2001; 86: 316-23.
13. Sastry SK, Burridge K. Focal adhesions: A nexus for intracellular signaling and cytoskeletal dynamics. Exp Cell Res 2000; 261: 25-36.
14. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-32.
15. Miranti CK, Brugge JS. Sensing the environment: A historical perspective on integrin signal transduction. Nat Cell Biol 2002; 4: E83-90.
16. Smyth SS, Patterson C. Tiny dancers: The integrin-growth factor nexus in angiogenic signaling. J Cell Biol 2002; 158: 17-21.
17. Rüegg C, Dormond O, Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: Which side to target? Endothelium 2002; 9: 151-60.
18. Eliceiri B P. Integrin and growth factor receptor crosstalk. Circ Res 2001; 89: 1104-10.
19. Rüegg C, Mariotti A. Vascular integrins: Pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 1997; 78: 83-7.
20. Hynes RO, Bader BL. Targeted mutations in integrins and their ligands: Their implications for vascular biology. Thromb Haemost 1997; 78: 83-7.
21. Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res 1999; 32: 501-10.
22. Sheppard D. In vivo functions of integrins: Lessons from null mutations in mice. Matrix Biol 2000; 19: 203-9.
23. Rupp PA, Little CD. Integrins in vascular development. Circ Res 2001; 89: 566-72.
24. Bouvard D, et al. Functional consequences of integrin gene mutations in mice. Circ Res 2001; 89: 211-23.
25. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 1993; 119: 1093-105.
26. Francis SE, Goh KL, Hodivala-Dilke K, et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 2002; 22: 927-33.
27. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 1995; 121: 549-60.
28. Bader BL, Rayburn H, Crowley D, et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95: 507-19.
29. McCarty JH, Monahan-Earley RA, Brown LF et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol 2002; 22: 7667-77.
30. McHugh KP, Hodivala-Dilke K, Zheng MH et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105: 433-40.
31. Huang X, Griffiths M, Wu J, et al. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol Cell Biol 2000; 20: 755-9.
32. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8: 27-34.
33. Tomiyama Y. Glanzmann thrombasthenia: Integrin alpha IIb beta 3 deficiency. Int J Hematol 2000; 72: 448-54.
34. Hynes RO, Hodivala-Dilke KM. Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia. Thromb Haemost 1999; 82: 481-5.
35. Huang XZ, Wu JF, Ferrando R, et al. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol 2000; 20: 5208-15.
36. Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J 2002; 21: 4593-9.
37. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 1996; 69-87.
38. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
39. Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 320-4.
40. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alpha V beta 3 - Targeted magnetic resonance imaging. Nat Med 1998; 4: 623-6.
41. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A 1987; 84: 6471-5.
42. Dechantsreiter MA, Planker E, Matha B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42: 3033-40.
43. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2.
44. Hammes HP, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-33.
45. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
46. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
47. Soldi R, Mitola S, Strasly M, et al. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 1999; 18: 882-92.
48. Eliceiri BP, et al. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol 1998; 140: 1255-63.
49. Brooks PC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-93.
50. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. Mol Cell 2000; 6: 851-60.
51. Scatena M, Almeida M, Chaisson ML, et al. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-93.
52. Stromblad S, Becker JC, Yebra M, et al. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996; 98: 426-33.
53. Stupack DG, Puente XS, Boutsaboualoy S, et al. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001; 155: 459-70.
54. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-21.
55. Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression in modulated by cytokines and during migration in vitro. Journal of Cell Science 1999; 112: 569-78.
56. Taverna D, Hynes RO. Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res 2001; 61: 5255-61.
57. Kim S, Bakre M, Yin H, Varner JA. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 2002; 110: 933-41.
58. Kim S, Harris M, Varner JA. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha 5beta 1 and protein kinase A J Biol Chem 2000; 275: 33920-8.
59. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995; 130: 1189-96.
60. Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003; 104: 496-503.
61. Senger DR, Claffey KP, Benes JE, et al. Angiogenesis promoted by vascular endothelial growth factor: Regulation through alpha1beta1 and alpha2beta1 integrins. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 13612-7.
62. Senger DR, Perruzzi CA, Streit M, et al. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 2002; 160: 195-204.
63. Funahashi Y, Sugi NH, Semba T, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res 2002; 62: 6116-23.
64. Pozzi A, Moberg PE, Miles LA, et al. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000; 97: 2202-7.
65. Pozzi A, Wary KK, Giancotti FG, et al. Integrin alpha1beta1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol 1998; 142: 587-94.
66. Gardner H, Broberg A, Pozzi A, et al. Absence of integrin alpha1beta1 in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J Cell Sci 1999; 112: 263-72.
67. Holtkotter O, Nieswandt B, Smyth N, et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002; 277: 10789-94.
68. Chen J, Diacovo TG, Grenache DG, et al. The alpha(2) integrin subunit-deficient mouse: A multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 2002; 161: 337-44.
69. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-16.
70. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-6.
71. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355: 646-8.
72. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-31.
73. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. Faseb J 1998; 12: 1063-73.
74. Coyne DW, Nickols M, Bertrand W, et al. Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids. Am J Physiol 1992; 263: F97-102.
75. Simmons DL, Levy DB, Yannoni Y, et al. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci U S A 1989; 86: 1178-82.
76. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
77. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
78. Muller-Decker K, Neufang G, Berger I, et al. Transgenic cyclooxgenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A 2002; 99: 12483-8.
79. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-9.
80. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-94.
81. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
82. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
83. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-31.
84. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
85. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
86. Dormond O, Foletti A, Paroz C, et al. NSAIDs inhibit alphaVbeta3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001; 7: 1041-7.
87. Dormond O, Bezzi M, Mariotti A, et al. Prostaglandin E2 promotes integrin aVb3-dependent endothelial cell adhesion, Rac-activation and spreading through cAMP/PKA signaling. J Biol Chem 2002; 277: 45838-46.
88. Soga N, Connolly JO, Chellaiah M, et al. Rac regulates vascular endothelial growth factor stimulated motility. Cell Comm Adhes 2001; 8: 1-13.
89. Kiosses WB, Hood J, Yang S, et al. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res 2002; 90: 697-702.
90. Shimizu Y, Van Seventer GA, Ennis E, et al. Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. J Exp Med 1992; 175: 577-82.
91. Van Willigen G, Akkerman JW. Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets. Biochem J 1991; 273: 115-20.
92. Haverstick DM, Gray LS. Lymphocyte adhesion mediated by lymphocyte function-associated antigen-1. II. Interaction between phorbol ester- and cAMP-sensitive pathways. J Immunol 1992; 149: 397-402.
93. Halvorson MJ, Coligan JE. Enhancement of VLA integrin receptor function on thymocytes by cAMP is dependent on the maturation stage of the thymocytes. J Immunol 1995; 155: 4567-74.
94. Lampugnani MG, Giorgi M, Gaboli M, et al. Endothelial cell motility, integrin receptor clustering, and microfilament organization are inhibited by agents that increase intracellular cAMP. Lab Invest 1990; 63: 521-31.
95. Lang P, Gesbert F, Delespine-Carmagnat M, et al. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. Embo J 1996; 15: 510-9.
96. Bakre MM, Zhu Y, Yin H, et al. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med 2002; 8: 995-1003.
97. Ydrenius L, Molony L, Ng-Sikorski J, et al. Dual action of cAMP-dependent protein kinase on granulocyte movement. Biochem Biophys Res Commun 1997; 235: 445-50.
98. Goldman AP, Williams CS, Sheng H, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998; 19: 2195-9.
99. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998; 19: 1939-42.
100. Daniel TO, Liu H, Morrow JD, et al. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-7.
101. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 1326-31.
102. Majima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000; 130: 641-9.
103. Zhang X, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190: 451-59.
104. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-4.
105. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 2002; 112: 839-43.
106. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002; 62: 2343-6.
107. Kundu N, Smyth MJ, Samsel L, et al. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Tr 2002; 76: 57-64.
108. Zweifel BS, Davis TW, Ornberg RL, et al. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002; 62: 6706-11.
109. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-45.
110. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000; 20: 2625-31.
111. Marrogi A, Pass HI, Khan M, et al. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000; 60: 3696-700.
112. Sheng H, Shao J, Kirkland SC, et al.. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-9.
113. Hsu AL, Ching TT, Wang DS, et al.. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-403.
114. Li M, Wu X, Xu XC. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int J Cancer 2001; 93: 218-23.
115. Jacoby RF, Seibert K, Cole CE, et al.. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-4.
116. Oshima M, Murai N, Kargman S, et al.. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-40.
117. Kawamori T, Rao CV, Seibert K, et al.. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
118. Reddy BS, Hirose Y, Lubet R, et al.. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293-7.
119. Howe LR, Subbaramaiah K, Patel J, et al.. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002; 62: 5405-7.
120. Abou-Issa HM, Alshafie GA, Seibert K, et al. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001; 21: 3425-32.
121. Alshafie GA, Abou-Issa HM, Seibert K, et al.. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000; 7: 1377-81.
122. Grubbs CJ, Lubet RA, Koki AT, et al.. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60: 5599-602.
123. Yoshimi N, Shimizu M, Matsunaga K, et al.. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999; 90: 406-12.
124. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998; 58: 5354-60.
125. Williams CS, Watson AJ, Sheng H, et al.. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045-51.
126. Yao M, Kargman S, Lam EC, et al.. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-92.
127. Tseng WW, Deganutti A, Chen MN, et al.. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastroint Surg 2002; 6: 838-43; discussion 844.
128. Sawaoka H, Tsuji S, Tsujii M, et al.. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-77.
129. Kishimoto Y, Yashima K, Morisawa T, et al.. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. J Gastroenterol 2002; 37: 186-93.
130. Liu X H, Kirschenbaum A, Yao S, et al.. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164: 820-5.
131. Sawaoka H, Kawano S, Tsuji S, et al.. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: G1061-7.
132. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93: 497-506.
133. Williams CS, Sheng H, Brockman JA, et al.. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 2001; 3: 428-36.
134. Trifan OC, Durham WF, Salazar VS, et al.. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-84.